title: Novel Strategies for the Treatment of Pseudomonas aeruginosa Infections.
abstract: Infections with Pseudomonas aeruginosa have become a concerning threat in hospital-acquired infections and for cystic fibrosis patients. The major problem leading to high mortality lies in the appearance of drug-resistant strains. Therefore, a vast number of approaches to develop novel anti-infectives is currently pursued. These diverse strategies span from killing (new antibiotics) to disarming (antivirulence) the pathogen. Particular emphasis lies on the development of compounds that inhibit biofilms formed in chronic infections to restore susceptibility toward antibiotics. Numerous promising results are summarized in this perspective. Antibiotics with a novel mode of action will be needed to avoid cross resistance against currently used therapeutic agents. Importantly, antivirulence drugs are expected to yield a significantly reduced rate of resistance development. Most developments are still far from the application. It can however be expected that combination therapies, also containing antivirulence agents, will pave the way toward novel treatment options against P. aeruginosa.
authors.affiliation: Chemical Biology of Carbohydrates, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) , D-66123 Saarbrücken, Germany.|Deutsches Zentrum für Infektionsforschung (DZIF) , 30625 Standort Hannover-Braunschweig, Germany.
authors.forename: Stefanie
authors.initials: S
authors.lastname: Wagner
authors.affiliation: Chemical Biology of Carbohydrates, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) , D-66123 Saarbrücken, Germany.|Deutsches Zentrum für Infektionsforschung (DZIF) , 30625 Standort Hannover-Braunschweig, Germany.
authors.forename: Roman
authors.initials: R
authors.lastname: Sommer
authors.affiliation: Deutsches Zentrum für Infektionsforschung (DZIF) , 30625 Standort Hannover-Braunschweig, Germany.|Drug Design and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) , D-66123 Saarbrücken, Germany.
authors.forename: Stefan
authors.initials: S
authors.lastname: Hinsberger
authors.affiliation: Deutsches Zentrum für Infektionsforschung (DZIF) , 30625 Standort Hannover-Braunschweig, Germany.|Drug Design and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) , D-66123 Saarbrücken, Germany.
authors.forename: Cenbin
authors.initials: C
authors.lastname: Lu
authors.affiliation: Deutsches Zentrum für Infektionsforschung (DZIF) , 30625 Standort Hannover-Braunschweig, Germany.|Drug Design and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) , D-66123 Saarbrücken, Germany.
authors.forename: Rolf W
authors.initials: RW
authors.lastname: Hartmann
authors.affiliation: Deutsches Zentrum für Infektionsforschung (DZIF) , 30625 Standort Hannover-Braunschweig, Germany.|Drug Design and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) , D-66123 Saarbrücken, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Empting
authors.affiliation: Chemical Biology of Carbohydrates, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) , D-66123 Saarbrücken, Germany.|Deutsches Zentrum für Infektionsforschung (DZIF) , 30625 Standort Hannover-Braunschweig, Germany.
authors.forename: Alexander
authors.initials: A
authors.lastname: Titz
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D018441:Biofilms / Q000187:drug effects; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D008958:Models, Molecular; D058990:Molecular Targeted Therapy / Q000379:methods*; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000472:pathogenicity / Q000502:physiology; D053038:Quorum Sensing / Q000187:drug effects
chemical_list: D000900:Anti-Bacterial Agents